Rating Change
Citigroup analysts initiated coverage on Hikma Pharmaceuticals PLC (OTC:HKMPY) with a Buy rating on July 16, 2026.
new coverageOTC:HKMPY
Citigroup Initiates Coverage on Hikma Pharmaceuticals PLC (HKMPY) with Buy
Rating Change Citigroup analysts initiated coverage on Hikma Pharmaceuticals PLC (OTC:HKMPY) with a Buy rating on July 16, 2026. Market Context Hikma Pharmaceuticals PLC operates…
Market Context
Hikma Pharmaceuticals PLC operates in the Healthcare sector. The stock currently trades at $41.99 with a market capitalization of $4.6B.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Hikma Pharmaceuticals PLC.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Hikma Pharmaceuticals PLC
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 16, 2026 | Citigroup | Buy | N/A |
| Jun 22, 2026 | Deutsche | Buy | N/A |
| May 05, 2026 | Jefferies | Buy | N/A |
| Apr 28, 2026 | Berenberg Bank | Buy | N/A |
| Mar 04, 2026 | Berenberg Bank | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View HKMPY Stock Page
Frequently Asked Questions
What does a Buy rating mean for HKMPY?
A Buy rating from Citigroup reflects the analyst's outlook on Hikma Pharmaceuticals PLC (OTC:HKMPY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the HKMPY forecast page.